Angiogenesis inhibitors generated by tumors.
作者信息
Folkman J
机构信息
Children's Hospital Boston, Massachusetts, USA.
出版信息
Mol Med. 1995 Jan;1(2):120-2.
Abstract
摘要
相似文献
1
Angiogenesis inhibitors generated by tumors.肿瘤产生的血管生成抑制剂。
Mol Med. 1995 Jan;1(2):120-2.
2
[Angiogenesis--principles and significance in urologic tumors].
Urologe A. 1996 Sep;35(5):357-62. doi: 10.1007/s001200050036.
3
4
Angiogenesis and antiangiogenic therapy.血管生成与抗血管生成疗法。
Curr Probl Cancer. 2002 Jan-Feb;26(1):1-60.
5
Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth.血管抑素：一种循环内皮细胞抑制剂，可抑制血管生成和肿瘤生长。
Cold Spring Harb Symp Quant Biol. 1994;59:471-82. doi: 10.1101/sqb.1994.059.01.052.
6
A new approach to fighting cancer?一种对抗癌症的新方法？
Proc Natl Acad Sci U S A. 1998 May 26;95(11):5843-4. doi: 10.1073/pnas.95.11.5843.
7
Thrombospondin as a regulator of angiogenesis.血小板反应蛋白作为血管生成的调节因子。
EXS. 1997;79:295-314. doi: 10.1007/978-3-0348-9006-9_12.
8
Anticancer drug targets: approaching angiogenesis.抗癌药物靶点：走近血管生成
J Clin Invest. 1999 Dec;104(11):1497-501. doi: 10.1172/JCI8849.
9
[Angiostatin. A biological inhibitor of tumor angiogenesis].[血管抑素。一种肿瘤血管生成的生物抑制剂]
Dtsch Med Wochenschr. 1997 Mar 27;122(13):413-4. doi: 10.1055/s-0029-1233709.
10
Are angiostatin and endostatin cures for cancer?血管抑素和内皮抑素能治愈癌症吗？
Lancet. 1998 May 30;351(9116):1598-9. doi: 10.1016/S0140-6736(98)22022-8.
引用本文的文献
1
Translationally Controlled Tumor Protein Enhances Angiogenesis in Ovarian Tumors by Activating Vascular Endothelial Growth Factor Receptor 2 Signaling.翻译调控肿瘤蛋白通过激活血管内皮生长因子受体2信号通路增强卵巢肿瘤血管生成。
Biomol Ther (Seoul). 2025 Jan 1;33(1):193-202. doi: 10.4062/biomolther.2024.206. Epub 2024 Dec 12.
2
Tumor angiogenesis and anti-angiogenic therapy.肿瘤血管生成与抗血管生成治疗。
Chin Med J (Engl). 2024 Sep 5;137(17):2043-2051. doi: 10.1097/CM9.0000000000003231. Epub 2024 Jul 25.
3
Tumor Microenvironment Features and Chemoresistance in Pancreatic Ductal Adenocarcinoma: Insights into Targeting Physicochemical Barriers and Metabolism as Therapeutic Approaches.胰腺导管腺癌的肿瘤微环境特征与化疗耐药性：针对物理化学屏障和代谢作为治疗方法的见解
Cancers (Basel). 2021 Dec 6;13(23):6135. doi: 10.3390/cancers13236135.
4
Antitumor effects of Endostar(rh-endostatin) combined with gemcitabine in different administration sequences to treat Lewis lung carcinoma.恩度（重组人血管内皮抑制素）与吉西他滨不同给药顺序联合应用对Lewis肺癌的抗肿瘤作用
Cancer Manag Res. 2019 Apr 23;11:3469-3479. doi: 10.2147/CMAR.S192868. eCollection 2019.
5
Differential activity of 16K rat prolactin in different organic systems.16K大鼠催乳素在不同有机系统中的差异活性。
Anim Cells Syst (Seoul). 2019 Feb 20;23(2):135-142. doi: 10.1080/19768354.2018.1554543. eCollection 2019 Apr.
6
Preclinical Pharmacokinetics of C118P, a Novel Prodrug of Microtubules Inhibitor and Its Metabolite C118 in Mice, Rats, and Dogs.C118P（微管抑制剂前药及其代谢物 C118 在小鼠、大鼠和犬中的临床前药代动力学研究。
Molecules. 2018 Nov 5;23(11):2883. doi: 10.3390/molecules23112883.
7
Hematopoietic Id Deletion Triggers Endomyocardial Fibrotic and Vascular Defects in the Adult Heart.造血 ID 缺失导致成年心脏的心内膜纤维化和血管缺陷。
Sci Rep. 2017 Jun 8;7(1):3079. doi: 10.1038/s41598-017-03160-7.
8
Primary melanoma tumor inhibits metastasis through alterations in systemic hemostasis.原发性黑色素瘤肿瘤通过改变全身止血来抑制转移。
J Mol Med (Berl). 2016 Aug;94(8):899-910. doi: 10.1007/s00109-016-1415-2. Epub 2016 Apr 6.
9
A Hypothesis Concerning the Biphasic Dose-response of Tumors to Angiostatin and Endostatin.关于肿瘤对血管抑素和内皮抑素双相剂量反应的一种假说。
Dose Response. 2015 May 20;13(2). doi: 10.2203/dose-response.14-020.Parris. eCollection 2015 Apr-Jun.
10
The anti-tumor effect is enhanced by simultaneously targeting VEGF and PROK1 in colorectal cancer.在结直肠癌中同时靶向血管内皮生长因子（VEGF）和前动力蛋白1（PROK1）可增强抗肿瘤效果。
Oncotarget. 2015 Mar 20;6(8):6053-61. doi: 10.18632/oncotarget.3474.
本文引用的文献
1
Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells.在胶质母细胞瘤细胞中诱导野生型p53表达后血管生成抑制剂的释放。
Nat Genet. 1994 Oct;8(2):171-6. doi: 10.1038/ng1094-171.
2
Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1.
Science. 1994 Sep 9;265(5178):1582-4. doi: 10.1126/science.7521539.
3
Tumor angiogenesis: therapeutic implications.肿瘤血管生成：治疗意义。
N Engl J Med. 1971 Nov 18;285(21):1182-6. doi: 10.1056/NEJM197111182852108.
4
The resistance of certain tissues to invasion: penetrability of explanted tissues by vascularized mesenchyme.某些组织对侵袭的抵抗力：血管化间充质对外植组织的穿透性。
Am J Pathol. 1973 Dec;73(3):765-74.
5
Induction of angiogenesis during the transition from hyperplasia to neoplasia.
Nature. 1989 May 4;339(6219):58-61. doi: 10.1038/339058a0.
6
Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene.一种癌症抑制基因对一种新型血管生成抑制剂活性的调控。
Cell. 1989 Feb 10;56(3):345-55. doi: 10.1016/0092-8674(89)90238-9.
7
Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha.巨噬细胞诱导的血管生成由肿瘤坏死因子-α介导。
Nature. 1987;329(6140):630-2. doi: 10.1038/329630a0.
8
Eponemycin, a novel antibiotic, is a highly powerful angiogenesis inhibitor.埃坡霉素是一种新型抗生素，是一种高效的血管生成抑制剂。
Biochem Biophys Res Commun. 1991 Dec 31;181(3):1070-6. doi: 10.1016/0006-291x(91)92046-m.
9
Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma.在纤维肉瘤的多步骤发展过程中，新血管生成与碱性成纤维细胞生长因子（bFGF）的输出转换相关。
Cell. 1991 Sep 20;66(6):1095-104. doi: 10.1016/0092-8674(91)90033-u.
10
Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis.细胞外基质驻留生长因子和酶：可能参与肿瘤转移和血管生成。
Cancer Metastasis Rev. 1990 Nov;9(3):203-26. doi: 10.1007/BF00046361.
Zotero 插件